Anti-CD19 Chimeric Antigen Receptor (CAR)-Transduced T Cell Therapy for Patients With B Cell Malignancies

NCT03076437 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

28

Enrollment

OTHER

Sponsor class

Conditions

Acute Lymphocytic Leukemia
Chronic Lymphocytic Leukemia
Lymphoma

Interventions

COMBINATION_PRODUCT: Drugs and Anti-CD19-CAR transduced T cells

Sponsor

Shenzhen Institute for Innovation and Translational Medicine

Collaborators

[object Object]